Drug developer Healing Biotechnology (OTC:CUBT) has refiled its utility to uplist to NYSE and conduct an $8M public providing after withdrawing its submitting in late October.
The Florida based mostly biopharma firm mentioned in a brand new S-1 submitting that it’s planning to supply 1.3M items priced at $6 per unit, a worth that would doubtless change. Every unit would consist of 1 share plus one warrant to purchase one share for $9.
Underwriters could be granted a 45-day choice to purchase an extra 15% of the whole shares and/or warrants bought to cowl any over-allotments. Aegis Capital is appearing as lead bookrunner.
Forward of the providing, Healing plans to conduct a 1-for-400 reverse inventory break up. The corporate’s shares are at the moment listed OTC underneath the image CUBT. It mentioned that it has been permitted to listing underneath the identical image on NYSE.
Healing is at the moment growing 4 in-licensed preclinical drug candidates as therapies for rabies, glioblastoma and age-related macular degeneration, together with a COVID-19 vaccine candidate for sufferers with kidney failure.
The biotech firm first filed an S-1 for the uplisting in April, stating in subsequent filings that it was looking for to boost round $8M. The corporate withdrew the S-1 on Oct. 31.